<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611790</url>
  </required_header>
  <id_info>
    <org_study_id>VS-002 / D</org_study_id>
    <nct_id>NCT03611790</nct_id>
  </id_info>
  <brief_title>Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)</brief_title>
  <official_title>The Vesalio Neva VS for the Treatment of Symptomatic Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage (aSAH) (The VITAL Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vesalio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vesalio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the safety and probable benefit of the Neva VS device&#xD;
      in patients presenting with symptomatic cerebral vasospasm despite maximal medical management&#xD;
      following aSAH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open label, single-arm study. Up to 30 eligible subjects at up to 15&#xD;
      sites will participate in the study. Subjects will be followed up for 30 days&#xD;
      post-intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>within 30 minutes of completion of procedure</time_frame>
    <description>defined as 50% or greater vessel caliber on DSA compared to baseline, as determined by the core laboratory</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeVa VS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeVa VS</intervention_name>
    <description>mechanical dilatation</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Subarachnoid hemorrhage secondary to ruptured aneurysm.&#xD;
&#xD;
          -  Ruptured aneurysm secured with surgical clipping or endovascular intervention.&#xD;
&#xD;
          -  Digital subtraction angiography (DSA) or CT angiography at the time of aSAH clinical&#xD;
             presentation or aSAH intervention with well-visualized intra-cerebral vessels is&#xD;
             available for review.&#xD;
&#xD;
          -  Vasospasm in one or more of the following: the internal carotid artery (ICA), basilar,&#xD;
             middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral&#xD;
             artery (PCA) territory on transcranial Doppler (TCD), and/or CT angiography, and/or&#xD;
             clinical signs of symptomatic vasospasm (change in level of consciousness, focal&#xD;
             neurological deficit) confirmed by &gt; 50% narrowing in these territories on DSA.&#xD;
&#xD;
          -  Vasospasm despite maximized medical management defined as oral Nimodipine (unless&#xD;
             contraindicated), systemic hypertension with SBP greater than 130 mmHg and euvolemia.&#xD;
&#xD;
          -  Target vessel pre-vasospasm diameter ≥ 2 mm and ≤ 4.0 mm.&#xD;
&#xD;
          -  Subject or legal representative is able and willing to give informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  The presence of an unsecured ruptured aneurysm. Note unsecured unruptured aneurysms&#xD;
             remote to the site of treated aSAH are not an exclusionary.&#xD;
&#xD;
          -  Symptoms attributable to other causes (e.g., hydrocephalus, metabolic, infection).&#xD;
&#xD;
          -  Hunt and Hess Grade of 5&#xD;
&#xD;
          -  Large infarct on CT scan defined as ASPECTS 0-5.&#xD;
&#xD;
          -  Intracranial hemorrhage not caused by aneurysm rupture.&#xD;
&#xD;
          -  History of bleeding disorders.&#xD;
&#xD;
          -  Baseline platelets &lt; 30,000.&#xD;
&#xD;
          -  International normalized ratio (INR) &gt; 1.7.&#xD;
&#xD;
          -  Any known contraindications to mechanical dilation of vasospastic vessels including&#xD;
             but not limited to:&#xD;
&#xD;
          -  Excessive vessel tortuosity that prevents the placement of the device&#xD;
&#xD;
          -  Evidence of rapidly improving neurological signs of stroke&#xD;
&#xD;
          -  Large territory completed cerebral infarction, edema with mass effect and&#xD;
             intra-parenchymal hemorrhage in vascular territory to be treated, or&#xD;
&#xD;
          -  any other vascular anatomic variants or anomalies&#xD;
&#xD;
          -  Pre-existing neurological or psychiatric disease that would confound the neurological&#xD;
             or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor&#xD;
             (e.g. Aricept).&#xD;
&#xD;
          -  History of severe allergy to contrast medium.&#xD;
&#xD;
          -  Known allergy to NeVa materials (nitinol, stainless steel).&#xD;
&#xD;
          -  Suspected or confirmed septic embolus, or bacterial endocarditis.&#xD;
&#xD;
          -  Septic shock or central nervous system (CNS) infection confirmed via cerebrospinal&#xD;
             fluid (CSF) sampling.&#xD;
&#xD;
          -  Known current or recent use of illicit drugs or alcohol abuse.&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the investigator, precludes an&#xD;
             endovascular procedure or poses a significant hazard to the subject if an endovascular&#xD;
             procedure is performed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RIA Neurovascular Clinic</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health System</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellstar Health System</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital - Northwell</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Health System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Sanders Regional Med Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TTUHSC El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

